Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
natural tags : Biotech save search
Natural Killer Cells Therapeutics Global Market Report 2022: Growing Focus of BioTech and Pharma Companies on Cost-Effective and Potent Treatments Boosts Sector
Published: 2022-12-28 (Crawled : 13:00) - prnewswire.com
IPHYF | $2.65 104.6% 300
|
Health Technology
|
| O: 4.47%
H: 0.0%
C: 0.0%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 2.43%
H: 0.0%
C: -0.57%
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.13%
H: 0.58%
C: -0.26%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.4%
H: 0.0%
C: 0.0%
NKTX | $7.78 -1.02% -1.03% 680K
|
Health Technology
|
| O: 0.0%
H: 6.03%
C: 2.33%
FATE | $5.04 -4.36% -4.56% 2.3M
|
Health Technology
|
| O: -0.59%
H: 2.96%
C: -2.76%
AFMD | $5.1 -2.49% -2.55% 90K
|
Health Technology
|
| O: 1.79%
H: 3.51%
C: 0.0%
pharma global companies report growing biotech natural therapeutics market
Brown Rice Market Size to Grow by USD 2.97 bn, Agistin Biotech Pvt. Ltd. and Amira Nature Foods Ltd. Among Key Vendors - Technavio
Published: 2022-11-04 (Crawled : 09:00) - prnewswire.com
ANFIF | $0.0001 19900.0% 680
|
Retail Trade
| Email alert
Add to watchlist
foods rice biotech market
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
Published: 2022-07-20 (Crawled : 13:20) - globenewswire.com
PRTG | $0.299 35.17% 26.02% 140K
|
Mining, Quarrying, and Oil and ...
|
| O: -1.23%
H: 19.49%
C: 7.45%
biotech platform
Worldwide Natural Killer Cells Therapeutics Industry to 2027 - Featuring Fate Therapeutics, Fortress Biotech and Ziopharm Oncology Among Others
Published: 2022-07-01 (Crawled : 20:00) - prnewswire.com
IPHA | $2.4 -0.42% -0.42% 11K
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
| Email alert
Add to watchlist
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
| Email alert
Add to watchlist
biotech therapeutics
Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature Medicine
Published: 2022-03-28 (Crawled : 15:20) - globenewswire.com
KRYS | $164.04 -3.3% -3.41% 280K
|
Health Technology
|
| O: -0.64%
H: 3.72%
C: 3.02%
trial biotech phase 1
Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep's Stimulation of Natural Killer Cell Anti-Cancer Activity
Published: 2022-03-17 (Crawled : 19:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 3.95%
H: 5.7%
C: 2.53%
biotech cel preclinical cancer iot pre-clinical
Wave Life Sciences Announces Nature Biotechnology Publication Highlighting First RNA Base Editing in Non-Human Primates Using an Endogenous Enzyme
Published: 2022-03-07 (Crawled : 18:00) - biospace.com/
WVE | $4.8 0.21% 0.21% 540K
|
Health Technology
|
| O: 1.29%
H: 0.0%
C: -11.06%
technology biotech life science iot
IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine
Published: 2021-12-09 (Crawled : 17:00) - globenewswire.com
IOBT | $1.5 1.95% 180K
|
|
| O: -2.3%
H: 0.95%
C: 0.0%
trial trial results phase 1 results biotech iot phase 2 phase 3
Purple Biotech Announces Publication in Nature Cancer Demonstrating Mechanisms Behind Cancer Cell Persistence Frequency and Potential of NT219 to Reduce Therapeutic Resistance
Published: 2021-10-22 (Crawled : 11:00) - globenewswire.com
PPBT | $0.4701 8.24% 7.62% 170K
|
Manufacturing
| Email alert
Add to watchlist
cancer potential biotech iot
GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature BiotechnologyArticle describes GigaGen’s technology and approach for the production of a new class of drug, recombinant hyperimmunes, including its novel COVID-19 therapy
Published: 2021-04-15 (Crawled : 19:00) - biospace.com/
GRFS | News | $6.53 -0.76% -0.77% 760K
|
Health Technology
|
| O: -0.06%
H: 3.08%
C: 2.35%
covid therapy biotech drug research technology iot
Burning Rock’s Liquid Biopsy Assay Achieved Strong Performance in the FDA-led SEQC2 Study, with Results Published on Nature Biotechnology
Published: 2021-04-13 (Crawled : 08:00) - globenewswire.com
BNR | $0.7728 -3.4% -3.52% 22K
|
Health Services
|
| O: 1.46%
H: 2.33%
C: -0.27%
fda results biotech technology iot
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.